Cellectis Drops Blood-Cancer CAR-Ts; Citizens Cuts Rating
Citizens cut Cellectis to Market Perform after it scrapped allogeneic CAR-T programs and pivoted to in-vivo gene editing for high triglycerides and cholesterol. Catalysts now 2027–28.
/ 1644 items
#XY↓
Contineum’s J&J-Partnered Depression Drug Misses Phase 2 Goal
Contineum said its J&J-partnered drug PIPE-307 missed the Phase 2 primary goal of improving MADRS scores at Day 5 versus placebo.
Johnson & Johnson Weighs $20 Billion Sale of Its Orthopedics Unit to Apollo
J&J is in talks to sell DePuy Synthes, its $9.3B hip-and-knee unit, to Apollo for about $20B. A deal could close in weeks—or J&J may spin it off.
GE HealthCare Eyes Sofie Biosciences Acquisition to Expand Imaging Chemicals
GE HealthCare is considering a deal worth up to $1 billion for Sofie Biosciences, which makes radiopharmaceuticals used in cancer PET scans.
GSK posts strong lung cancer data at WCLC as it seeks first-line Jideytro approval
Jideytro shrank tumors in 94% of untreated ROS1 patients; Ris-Rez cut death risk 54% vs topotecan in China. FDA filing planned this year.
B. Riley Turns Bullish on Capricor Before November Deramiocel Decision
B. Riley upgrades Capricor to Buy from Neutral and lifts its target to $21 from $5 ahead of the Nov. 22, 2026 deramiocel FDA date.